Hematology AdvisorAntimetabolite Therapies May Increase Prevalence of CHIP in Pediatric Cancer Survivors

ℹ️ Observational Association Only Evidence
A retrospective analysis of 1,052 pediatric cancer patients presented at AACR 2026 examined clonal hematopoiesis of indeterminate potential (CHIP) prevalence and treatment associations. Overall CHIP prevalence was low, with antimetabolite therapy emerging as the strongest treatment-related signal.

Clinical Considerations

• CHIP mutations appeared in 2.2% of the cohort, with TET2, DNMT3A, and KRAS as the most frequently identified variants.
• Chemotherapy exposure trended toward higher CHIP prevalence (3.3% vs 1.4%, P=.055), approaching but not reaching conventional significance.
• Antimetabolite therapy showed the strongest association (OR 3.46, P=.048), driven predominantly by methotrexate exposure (OR 21.5, P=.001).
• External beam radiotherapy was not associated with CHIP prevalence in this cohort.

Practice Applications

• Recognize CHIP as an emerging signal in pediatric cancer survivorship requiring longitudinal characterization.
• Interpret the methotrexate association as hypothesis-generating pending validation in prospective cohorts.
• Monitor evolving evidence on long-term hematologic implications in pediatric survivors.
• Avoid translating these findings into surveillance or treatment modifications outside research protocols.

More in CHIP